GlobeNewswire

Transactions in connection with and conclusion of share buy-back program
09/11/2026
Company announcement no. 45 - 26 09 November 2026 Transactions in connection with and conclusion of share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as [...]
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2026
09/11/2026
Tokyo, Japan and Cambridge, UK, 9 November 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies [...]
Epitopea annonce l'administration de la première dose à une patiente dans le cadre de l'essai clinique OVACT de phase 1/1b portant sur le CryptiVaxTM-1001 dans le cancer de l'ovaire séreux de haut grade avancé
09/11/2026
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 09 nov. 2026 (GLOBE NEWSWIRE) -- Epitopea, une société de biotechnologie au stade clinique développant des vaccins anticancéreux prêts à l’emploi et durables à base d’ARN, a annoncé [...]
Epitopea Announces First Patient Dosed in OVACT Phase 1/1b Clinical Trial of CryptiVax™-1001 in Advanced High-Grade Serous Ovarian Cancer
09/11/2026
CAMBRIDGE, UK and MONTREAL, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Epitopea, a clinical-stage, biotech company developing off-the-shelf, durable RNA-based cancer vaccines, announced today that the first patient has been [...]
Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
09/11/2026
Deal valued at more than $140 million in upfront and potential milestone payments, plus double-digit royalties. Kyorin obtains exclusive rights to develop and commercialize paridiprubart, an anti-TLR4 monoclonal [...]
Biodesix to Showcase MRD Strategy at the Association for Molecular Pathology (AMP) 2026 Annual Meeting
09/11/2026
New data highlighting proprietary bioinformatics, ultrasensitive molecular detection, and collaborations with Bio-Rad Laboratories and Thermo Fisher Scientific to advance scalable MRD solutions for clinical laboratories [...]
Codexis Advances ECO Synthesis Toward Adoption Readiness with Quality at Scale and Expanded siRNA Manufacturing Capabilities
09/11/2026
Data shared at TIDES Europe demonstrates consistent and robust platform performance while delivering high product quality at scale, alongside new platform capabilities in targeting functionality and initial results [...]
DeepLife and 3billion partner to discover small-molecule therapeutics against genetic modifier targets across multiple diseases
09/11/2026
The collaboration combines DeepLife's AI virtual-cell platform, TwinCell, with 3billion's genomics and AI-driven medicinal chemistry technology, to create an end-to-end engine for discovering genetic modifier targets [...]
argenx to Acquire Unnatural Products, Inc., Adding Peptide Discovery Engine to Broaden Immunology Capabilities
09/11/2026
Pairs Unnatural Products’ (UNP) peptide expertise with argenx's antibody engineering, expanding the ways to target novel biology Extends argenx’s immunology innovation to more patients, with the potential for oral and [...]
ACR 2026: Dapirolizumab Pegol Associated with Greater Treatment Response Rates Versus Placebo in SLE Using Novel Treatment Response Measure
09/11/2026
Dapirolizumab pegol (DZP) associated with higher response rates using the novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): A post-hoc analysis applying TRM-SLE to the DZP Phase 3 PHOENYCS GO [...]
Unnatural Products to be Acquired by argenx for up to $1.15 Billion to Advance Next-Generation Medicines
09/11/2026
Argenx to acquire UNP for $550 million upfront plus contingent value rights tied to development and regulatory milestones, for total potential value of up to approximately $1.15 billion Acquisition builds on the two- [...]
Valneva annonce des résultats positifs de phase 2 pour son candidat vaccin tétravalent contre la shigellose S4V2
09/11/2026
Les données de l’essai d’immunogénicité et de sécurité chez les nourrissons ainsi que de l’étude d’infection humaine contrôlée (CHIM) montrent un profil de sécurité favorable et des signaux prometteurs d’immunogénicité [...]
Valneva Announces Positive Phase 2 Results for Tetravalent Shigella Vaccine Candidate S4V2
09/11/2026
Data from infant immunogenicity and safety trial, and controlled human infection model (CHIM) trial, demonstrate favorable safety profile with encouraging immunogenicity and efficacy signals Lyon (France), November 9, [...]
Essential Pharma and Nordmark announce new partnership and UK availability of Norzyme® (pancreas powder) 25,000 gastro-resistant capsules for pancreatic exocrine insufficiency
09/11/2026
Partnership brings together decades of pancreatin experience at Nordmark and Essential Pharma Norzyme ® (pancreas powder) 25,000 gastro-resistant capsules, a Nordmark medicine, has received its UK marketing [...]
GENFIT présente les données issues des études cliniques de nangibotide soutenant la poursuite de son développement dans l’ACLF. Résultats de phase 2 attendus en 2027
09/11/2026
Un ensemble complet de données cliniques et scientifiques solides soutenant le développement de Phase 2 de nangibotide dans l’ACLF présenté aux experts internationaux lors du congrès AASLD The Liver Meeting®. Un [...]
GENFIT Highlights Data from Clinical Studies of Nangibotide, Supporting Its Advancement into ACLF with Phase 2 Data Expected in 2027
09/11/2026
Comprehensive clinical and scientific data supporting Phase 2 development of nangibotide in ACLF unveiled to leading experts during AASLD The Liver Meeting® Strong biological rationale in ACLF: TREM-1 modulation is [...]
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
09/11/2026
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today [...]
Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
09/11/2026
ZUG, Switzerland, November 9, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations in neuro-ophthalmology and ophthalmology, today [...]
iDEL Therapeutics Enters Global Research Collaboration with Daiichi Sankyo to Develop Multi-Drug Conjugate with Targeted Cytosolic Delivery into Solid Tumor Cells
09/11/2026
— Collaboration’s objective is to evaluate the potential of a cancer therapeutic by using iDEL’s unique shuttle technology platform — Dortmund, Germany, November 09, 2026 — iDEL Therapeutics today announced that it has [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum